Hormonal Therapy for Prostate Cancer: When to Use It

Area of Science:

• Oncology
• Urology
• Endocrinology

Background:

• Androgen deprivation therapy (ADT) is the established standard treatment for advanced prostate cancer.
• The development of antiandrogen drugs has enabled combination hormonal therapy, achieving total androgen blockade.
• Total androgen blockade has demonstrated superior efficacy compared to monotherapy in patients with low-tumor-burden metastatic disease.

Purpose of the Study:

• To evaluate the efficacy of combination hormonal therapy in advanced prostate cancer.
• To assess the benefits of total androgen blockade in metastatic and locally advanced disease.
• To summarize current research trends and ongoing clinical trials.

Main Methods:

• Review of existing clinical studies and phase II trials.
• Analysis of data comparing combination hormonal therapy with monotherapy.
• Ongoing phase III randomized controlled trials are being conducted to further validate findings.

Main Results:

• Combination hormonal therapy (total androgen blockade) is superior to monotherapy for metastatic prostate cancer with low tumor burden.
• Phase II studies suggest that combination therapy may prolong disease-free survival in locally advanced prostate cancer.
• Ongoing phase III trials are expected to provide definitive evidence.

Conclusions:

• Combination hormonal therapy represents a significant advancement in treating advanced prostate cancer.
• The strategy of total androgen blockade is increasingly adopted for both metastatic and locally advanced prostate cancer.
• Further research through phase III trials is crucial to solidify the role of combination therapy in clinical practice.